The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer

被引:41
作者
Spring, Laura M. [1 ,2 ]
Bar, Yael [1 ]
Isakoff, Steven J. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Harvard Med Sch, Boston, MA 02115 USA
来源
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2022年 / 20卷 / 06期
关键词
PATHOLOGICAL COMPLETE RESPONSE; CONTROLLED SUPERIORITY TRIAL; FREE CHEMOTHERAPY REGIMENS; DE-ESCALATION STRATEGIES; LONG-TERM EFFICACY; PHASE-II TRIAL; ENDOCRINE THERAPY; OPEN-LABEL; ANTHRACYCLINE-FREE; RANDOMIZED-TRIAL;
D O I
10.6004/jnccn.2022.7016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The role of neoadjuvant therapy (NAT) for localized breast cancer has evolved tremendously over the past several years. Currently, NAT is the preferred option for high-risk early triple-negative (TN) and HER2-positive (HER2+) breast cancers and is indicated for some estrogen receptor-positive (ER+) breast cancers. In addition to traditional absolute indications for NAT, relative indications such as the assessment of outcomes at the time of surgery and guidance of treatment escalation and de-escalation have greatly evolved in recent years. Pathologic complete response (pCR) and the Residual Cancer Burden (RCB) index are highly prognostic for disease recurrence and survival, mainly in patients with TN or HER2+ disease. Furthermore, post-NAT escalation strategies have been shown to improve long-term outcomes of patients who do not achieve pCR. Additionally, by allowing the direct assessment of drug effect on the tumor, the neoadjuvant setting has become an attractive setting for the exploration of novel agents and the identification of predictive biomarkers. Neoadjuvant trial design has also evolved, using adaptive treatment approaches that enable treatment de-escalation or escalation based on response. However, despite multiple practice-changing neoadjuvant trials and the addition of various new agents to the neoadjuvant setting for early breast cancer, many key questions remain. For example, patient selection for neoadjuvant immunotherapy in TN breast cancer, de-escalation methods in HER2+ breast cancer, and the use of gene expression profiles to guide NAT recommendations in ER+ breast cancer. This article reviews the current approach for NAT in localized breast cancer as well as evolving NAT strategies, the key remaining challenges, and the ongoing work in the field.
引用
收藏
页码:723 / 734
页数:12
相关论文
共 50 条
  • [41] Neoadjuvant endocrine therapy in breast cancer
    Abrial, C
    Mouret-Reynier, MA
    Curé, H
    Feillel, V
    Leheurteur, M
    Lemery, S
    Le Bouëdec, G
    Durando, X
    Dauplat, J
    Chollet, P
    BREAST, 2006, 15 (01) : 9 - 19
  • [42] Neoadjuvant Endocrine Therapy in Breast Cancer
    Singer, Christian F.
    BREAST CARE, 2008, 3 (05) : 303 - 308
  • [43] Neoadjuvant system therapy for breast cancer
    Von Minckwitz G.
    Untch M.
    Der Gynäkologe, 2012, 45 (6): : 453 - 459
  • [44] Neoadjuvant Endocrine Therapy for Breast Cancer
    Chawla, Jane S.
    Ma, Cynthia X.
    Ellis, Matthew J.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 19 (03) : 627 - +
  • [45] Neoadjuvant Therapy in the Treatment of Breast Cancer
    Teshome, Mediget
    Hunt, Kelly K.
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 23 (03) : 505 - +
  • [46] Neoadjuvant endocrine therapy in breast cancer
    Beresford, M. J.
    Ravichandran, D.
    Makris, A.
    CANCER TREATMENT REVIEWS, 2007, 33 (01) : 48 - 57
  • [47] Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
    Litton, Jennifer K.
    Scoggins, Marion E.
    Hess, Kenneth R.
    Adrada, Beatriz E.
    Murthy, Rashmi K.
    Damodaran, Senthil
    DeSnyder, Sarah M.
    Brewster, Abenaa M.
    Barcenas, Carlos H.
    Valero, Vicente
    Whitman, Gary J.
    Schwartz-Gomez, Jill
    Mittendorf, Elizabeth A.
    Thompson, Alastair M.
    Helgason, Thorunn
    Ibrahim, Nuhad
    Piwnica-Worms, Helen
    Moulder, Stacy L.
    Arun, Banu K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [48] The role of magnetic resonance imaging on evaluating response of neoadjuvant therapy for breast cancer
    Guo, Liang-cun
    Du, Si-yao
    Yang, Xiao-ping
    Li, Shu
    Zhang, Li-na
    CHINESE JOURNAL OF ACADEMIC RADIOLOGY, 2020, 3 (03) : 125 - 136
  • [49] HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
    Dent, Susan
    Oyan, Basak
    Honig, Amd
    Mano, Max
    Howell, Sacha
    CANCER TREATMENT REVIEWS, 2013, 39 (06) : 622 - 631
  • [50] Treatment of residual disease following neoadjuvant therapy in breast cancer
    Heater, Natalie K.
    Somayaji, Khyati
    Gradishar, William
    JOURNAL OF SURGICAL ONCOLOGY, 2024, 129 (01) : 18 - 25